AALL2121: A Phase 2 Study of SNDX-5613 in Combination with Chemotherapy for Patients with Relapsed or Refractory KMT2A-Rearranged Infant Leukemia
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Cancer Research -
Location
-
Principal Investigator
-
Sponsor
Children's Oncology Group/SYNDAX
The overall goal of this study is to determine the safety and best dose of the drug SNDX-5613 for young children when given in combination with chemotherapy, and to see if this treatment will improve the outcome of children with relapsed or refractory KMT2A-R leukemia
Enrollment Form
This study is currently enrolling.